Barclays PLC increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 541,093 shares of the biotechnology company's stock after purchasing an additional 12,464 shares during the period. Barclays PLC owned approximately 0.23% of ADMA Biologics worth $9,279,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth $35,000. Vision Financial Markets LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth $51,000. AlphaQuest LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth $84,000. Finally, CIBC Private Wealth Group LLC raised its position in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.
View Our Latest Analysis on ADMA
ADMA Biologics Stock Performance
Shares of ADMA Biologics stock traded up $2.65 during trading hours on Monday, hitting $24.51. 10,253,257 shares of the company's stock traded hands, compared to its average volume of 3,671,345. ADMA Biologics, Inc. has a 12-month low of $6.49 and a 12-month high of $25.67. The stock has a market capitalization of $5.82 billion, a price-to-earnings ratio of 87.54 and a beta of 0.53. The company has a fifty day simple moving average of $18.97 and a 200-day simple moving average of $18.33. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
